|1.||Stein, C A: 15 articles (04/2009 - 12/2001)|
|2.||Benimetskaya, Luba: 12 articles (04/2009 - 10/2003)|
|3.||Marcucci, Guido: 10 articles (01/2010 - 01/2003)|
|4.||Liu, Shujun: 9 articles (01/2010 - 04/2005)|
|5.||Miller, Paul: 9 articles (04/2009 - 05/2004)|
|6.||Lee, Robert J: 8 articles (06/2011 - 05/2006)|
|7.||Lai, Johnathan C: 7 articles (04/2007 - 05/2004)|
|8.||Yu, Bo: 6 articles (06/2011 - 06/2009)|
|9.||Lee, L James: 6 articles (06/2011 - 06/2009)|
|10.||Chanan-Khan, Asher: 5 articles (06/2011 - 11/2004)|
|1.||Melanoma (Melanoma, Malignant)
01/01/2007 - "Genta believes that analysis sought to discredit the finding that treatment with oblimersen significantly increased progression-free survival; ODAC previously agreed this endpoint would support full approval in the absence of a survival improvement in patients with advanced melanoma.A rolling NDA submission was submitted to the FDA in the third quarter of 2003; however, Genta and Aventis withdrew the NDA after the application failed to gain marketing approval from the FDA's Oncology Drug Advisory Committee (ODAC). "
06/01/2014 - "To confirm and expand on this observation, we conducted a prospective double-blind, placebo-controlled study to determine whether oblimersen augmented the efficacy of Dac in advanced melanoma patients with low-normal baseline LDH levels. "
07/01/2009 - "LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)."
01/01/2007 - "Genta will conduct another phase III study of oblimersen in patients with advanced melanoma. "
01/01/2007 - "In May 2004, ODAC voted that phase III trial results did not provide substantial evidence of effectiveness to outweigh toxicity of oblimersen treatment in patients with metastatic melanoma. "
01/01/2011 - "The efficacy of this treatment was due to the higher G3139 uptake in tumor cells which led to a marked down-regulation of bcl-2 protein expression. "
07/15/2006 - "When treatment was delayed until tumor was established, G3139 in combination with CDDP significantly inhibited tumor growth compared to CDDP or CDDP + control oligo, and cured 69% animals with established tumors. "
06/01/2009 - "In addition, Tf-LP-G3139 was found to be more effective in tumor growth inhibition and prolonging mouse survival than free G3139. "
01/01/2009 - "In this study, a novel formulation of lipid nanoparticles (LNPs) encapsulating G3139 was synthesized and evaluated in mice bearing L1210 subcutaneous tumors. "
10/01/2007 - "Oblimersen, a Bcl-2 antisense phosphorothioate oligonucleotide, is being evaluated in patients with CLL and other cancers; trials through Phase III have been completed. "
|3.||Prostatic Neoplasms (Prostate Cancer)
10/01/2003 - "Although treatment of PC3 prostate cancer cells with G3139, which contains two CpG motifs, causes a dramatic decrease in bcl-2 protein expression after 3 days, it did not result in significant cellular apoptosis, as it does in many other cell lines. "
10/01/2010 - "Radiation was shown to increase intracellular and intratumoural penetration of oblimersen, confirming previous results obtained in prostate cancer xenograft models. "
12/01/2011 - "This study aimed to investigate the efficacy of G3139 combined with epirubicin in the androgen-independent prostate cancer. "
02/01/2005 - "Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer."
07/01/2009 - "This randomized, phase II study assessed the activity of oblimersen sodium, a Bcl-2 antisense oligonucleotide, administered before docetaxel (Taxotere) to patients with castration-resistant prostate cancer. "
12/01/2004 - "G3139, under optimal transfection conditions, decreased the proliferation rate of lymphoma cells by 60-75% when compared with controls. "
12/01/2004 - "Our findings suggest that Bcl-2 downregulation by G3139, followed by the administration of rituximab is an efficient anti-tumour strategy associated with improved survival in lymphoma-bearing SCID mice."
04/01/1997 - "An 18-mer full-phosphorothioate oligonucleotide with sequence antisense to the first six codons of the open reading frame of bcl-2 (G3139) has shown efficacy against the DoHH2 lymphoma implanted in severe combined immunodeficient mice. "
08/01/2007 - "To study the combinational effects of bcl-2 antisense oligodeoxynucleotide (bcl-2 ASODN) and Rituximab (anti-CD20 monoclonal antibody) on proliferation and apoptosis of B-lymphoma Raji cells in vitro and in vivo, and to explore the possible mechanisms. "
08/01/2007 - "[Combinational effects of bcl-2 antisense oligodeoxynucleotide and Rituximab on proliferation and apoptosis of B-lymphoma Raji cells]."
01/01/2007 - "Oblimersen received orphan drug status in the US and EU for multiple myeloma in September 2001. "
11/01/2004 - "Combining oblimersen with other anticancer agents represents a therapy-enhancing strategy to reverse the multidrug resistance seen in multiple myeloma (MM). "
01/01/2003 - "These data support further clinical evaluation of G3139 therapy in multiple myeloma."
09/01/2006 - "Randomized phase III trials are currently underway to evaluate whether the combined use of Oblimersen with standard treatment is superior to standard treatment alone in chronic lymphocytic leukaemia, malignant melanoma and multiple myeloma. "
01/01/2007 - "In addition, fast-track designation was given to oblimersen by the FDA in the same month.A phase I/II clinical study (NCT00062244) of oblimersen was conducted by the NCI in patients with Waldenstrom's macroglobulinaemia, a disease that is similar to multiple myeloma. "
|8.||L-Lactate Dehydrogenase (Lactate Dehydrogenase)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Combination Drug Therapy (Combination Chemotherapy)